Search: onr:"swepub:oai:DiVA.org:oru-113317" >
Real-World Outcomes...
-
Lamichhane, N.School of Health and Medical Sciences, Örebro University, Örebro, Sweden,Orebro Univ, Sweden
(author)
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
- Article/chapterEnglish2024
Publisher, publication year, extent ...
-
2024
-
Kluwer Academic Publishers,2024
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-113317
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113317URI
-
https://doi.org/10.1007/s10620-024-08422-9DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-203093URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Open access funding provided by Örebro University. This work was funded by Takeda Pharma AB (VedolizumabSC-4002); the Regional Agreement on Medical Training and Clinical Research between Region Örebro County and Örebro University: ALF (grant number OLL-836791 to CE).
-
Funding Agencies|Orebro University [OLL-836791]; Takeda Pharma AB [VedolizumabSC-4002]; Region Orebro County [OLL-836791]
-
BACKGROUND: Real-world data on starting intravenous (IV) vedolizumab (VDZ) and transitioning to subcutaneous (SC) treatment in inflammatory bowel disease (IBD) are scarce. AIMS: To assess treatment outcomes of patients with IBD starting IV VDZ and switching to SC VDZ in routine clinical care.METHODS: Adult patients with IBD switching from IV to SC VDZ treatment between 1 March 2020 and 31 December 2021 were identified from the Swedish IBD quality register. The primary outcome was SC VDZ persistence. Secondary outcomes included clinical remission, changes in quality of life (QoL) according to EuroQual 5-Dimensions 5-Levels (EQ-5D-5L) and the Short-Health Scale (SHS) and inflammatory markers, including faecal Calprotectin (FCP).RESULTS: Altogether, 406 patients with IBD (Crohn's disease, n = 181; ulcerative colitis, n = 225) were identified. After a median follow-up of 30 months from starting IV VDZ treatment, the persistence rates were 98%(178/181) in Crohn's disease and 94% (211/225) in ulcerative colitis. Most patients (84%) transitioned during maintenance therapy, and the median follow-up from switch to SC VDZ was 10 months. Compared to baseline, statistically significant improvements were observed in all domains of the SHS, EQ-5D index value and visual analogue scale. Median (interquartile range) FCP concentrations (μg/g) decreased from 459 (185-1001) to 65 (26-227) in Crohn's disease (n = 45; p < 0.001) and from 646 (152-1450) to 49 (20-275) in ulcerative colitis (n = 58; p < 0.001).CONCLUSION: Initiating IV VDZ and switching to SC treatment was associated with high persistence rates and improvements in measures of QoL and FCP. These findings are reassuring for patients who start IV VDZ and switch to SC VDZ.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Melas, N.School of Health and Medical Sciences, Örebro University, Örebro, Sweden; Central Hospital in Karlstad, Karlstad, Sweden,Orebro Univ, Sweden; Cent Hosp Karlstad, Sweden
(author)
-
Bergqvist, V.Department of Gastroenterology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden,Skane Univ Hosp, Sweden; Lund Univ, Sweden
(author)
-
Ekholm, N-P.Takeda Pharma, Medical Affairs, Stockholm, Sweden
(author)
-
Olén, O.Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Stockholm South General Hospital, Sachs' Children and Youth Hospital, Stockholm, Sweden; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Sweden; Stockholm South Gen Hosp, Sweden; Karolinska Inst, Sweden
(author)
-
Ludvigsson, Jonas F.,1969-Region Örebro län,Department of Paediatrics, Örebro University Hospital, Örebro, Sweden; Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY, USA; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden,Orebro Univ Hosp, Sweden; Columbia Univ, NY USA; Karolinska Inst, Sweden(Swepub:oru)jsln
(author)
-
Hjortswang, HenrikLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken(Swepub:liu)henhj44
(author)
-
Marsal, J.Department of Gastroenterology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Lund, Sweden,Skane Univ Hosp, Sweden; Lund Univ, Sweden
(author)
-
Eriksson, Carl,1981-Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Karolinska Inst, Sweden; Orebro Univ, Sweden(Swepub:oru)clen
(author)
-
Halfvarson, Jonas,1970-Örebro universitet, Institutionen för medicinska vetenskaper,Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Orebro Univ, Sweden(Swepub:oru)jshn
(author)
-
SWIBREG, -
(contributor)
-
School of Health and Medical Sciences, Örebro University, Örebro, SwedenOrebro Univ, Sweden
(creator_code:org_t)
Related titles
-
In:Digestive Diseases and Sciences: Kluwer Academic Publishers0163-21161573-2568
Internet link
Find in a library
To the university's database
- By the author/editor
-
Lamichhane, N.
-
Melas, N.
-
Bergqvist, V.
-
Ekholm, N-P.
-
Olén, O.
-
Ludvigsson, Jona ...
-
show more...
-
Hjortswang, Henr ...
-
Marsal, J.
-
Eriksson, Carl, ...
-
Halfvarson, Jona ...
-
SWIBREG, -
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Gastroenterology ...
- Articles in the publication
-
Digestive Diseas ...
- By the university
-
Örebro University
-
Linköping University